title: Human immunodeficiency virus type 1 neutralization by plasma from B or F genotype infected individuals.
abstract: Anti-human immunodeficiency virus type 1 (HIV-1) "binding antibodies" (antibodies capable of binding to synthetic peptides or proteins) occur throughout HIV-1 infection, are high-titered and highly cross-reactive, as confirmed in this study by analyzing plasma from B and F genotype HIV-1 infected individuals. Plasma from individuals infected with clade F HIV-1 displayed the most frequent cross-reactivity, in high titers, while Bbr plasma showed much higher specificity. Similarly, neutralization of a reference HIV-1 isolate (HIV-1 MN) was more frequently observed by plasma from F than B genotype infected individuals. No significant difference was seen in neutralization susceptibility of primary B, Bbr or F clade HIV-1 by plasma from individuals infected with the classical B (GPGR) or F HIV-1, but Bbr (GWGR) plasma were less likely to neutralize the F genotype primary HIV-1 isolates. The data indicate that both B and F genotype derived vaccines would be equally effective against B and F HIV-1 infection, with a slightly more probable effectiveness for F than B genotype. Although the Bbr variant appears to induce a much more specific humoral immune response, the susceptibility in neutralizing the Brazilian HIV-1 B genotype Bbr variant is similar to that observed with the classical B genotype HIV-1.
authors.affiliation: Laboratório de Aids e Imunologia Molecular, Departamento de Imunologia, Instituto Oswaldo Cruz-Fiocruz, 21045-900 Rio de Janeiro, RJ, Brazil. bongertz@ioc.fiocruz.br
authors.forename: V
authors.initials: V
authors.lastname: Bongertz
authors.forename: S L M
authors.initials: SL
authors.lastname: Teixeira
authors.forename: B
authors.initials: B
authors.lastname: Grinztejn
authors.forename: J H
authors.initials: JH
authors.lastname: Pilotto
authors.forename: V G
authors.initials: VG
authors.lastname: Veloso
authors.forename: M G
authors.initials: MG
authors.lastname: Morgado
authors.forename: F I
authors.initials: FI
authors.lastname: Bastos
authors.forename: E P
authors.initials: EP
authors.lastname: Ouverney
mesh_terms: D016915:AIDS Vaccines; D000918:Antibody Specificity / Q000235:genetics / Q000276:immunology*; D003429:Cross Reactions / Q000235:genetics / Q000276:immunology; D005260:Female; D005838:Genotype; D015483:HIV Antibodies / Q000276:immunology*; D015488:HIV Antigens / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D008297:Male; D009500:Neutralization Tests / Q000379:methods; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies; D015488:HIV Antigens; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments